By Fineline Cube 
HanchorBio, Inc. and WuXi Biologics (HKG: 2269) announced a strategic collaboration under which WuXi Biologics will provide integrated end‑to‑end development and manufacturing services for HanchorBio’s pipeline of next‑generation bifunctional and multifunctional fusion proteins, leveraging HanchorBio’s proprietary FBDB platform technology.
Deal Structure
| Item | Detail |
|---|---|
| Companies | HanchorBio, Inc. (Taiwan) and WuXi Biologics (HKEX: 2269) |
| Agreement Type | Strategic collaboration |
| Scope | Development and production of multiple next‑generation bifunctional/multifunctional fusion proteins |
| Services | Cell line development, process/bioanalytical method development, formulation development, GMP manufacturing |
| Platform | HanchorBio’s FBDB (Fusion protein Drug Discovery and Development) platform |
| Financial Terms | Not disclosed |
| Strategic Goals | Enhance CMC execution efficiency, accelerate clinical translation, enable scalable global development |
Technology Profile & Strategic Rationale
- FBDB Platform: HanchorBio’s proprietary Fusion protein Drug Discovery and Development technology enables creation of bifunctional and multifunctional biologics with enhanced targeting and therapeutic efficacy
- Integrated Services: WuXi Biologics provides end‑to‑end capabilities from cell line development through GMP manufacturing, streamlining the path from discovery to clinical trials
- Manufacturing Scale: Collaboration enables scalable global production of complex fusion proteins, addressing a key bottleneck in biologics development
- Market Position: Positions HanchorBio to advance its innovative fusion protein portfolio while leveraging WuXi Biologics’ world‑leading CRDMO infrastructure (200+ global projects)
Market Context
- Fusion Protein Market: Global market for bifunctional/multifunctional fusion proteins projected to reach $45 billion by 2030, driven by demand for next‑generation biologics with improved efficacy and reduced dosing frequency
- CRDMO Growth: Asia‑Pacific CRDMOs capturing increasing share of global biologics manufacturing due to cost efficiency and technical capabilities
- Competitive Advantage: Partnership combines HanchorBio’s novel platform technology with WuXi Biologics’ proven manufacturing track record
Forward‑Looking Statements
This brief contains forward‑looking statements regarding collaboration execution, pipeline advancement, and manufacturing timelines. Actual results may differ due to technical challenges, regulatory requirements, and market conditions.-Fineline Info & Tech